Acute On Chronic Liver Failure (ACLF) - Market Insight, Epidemiology, and Market Forecast - 2036

Acute on Chronic Liver Failure (ACLF) Insights and Trends

• ACLF market is witnessing strong growth across the leading markets, including the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, during the study period, driven by the increasing burden of chronic liver diseases and the growing demand for effective targeted therapies.
• A significant proportion of ACLF burden is associated with underlying chronic liver conditions and comorbidities such as alcohol-related liver disease, viral hepatitis, nonalcoholic steatohepatitis (NASH), sepsis, kidney dysfunction, and metabolic disorders, with alcohol-related liver disease contributing the largest share, highlighting the need for integrated disease management, early intervention, infection control, and targeted therapeutic approaches to reduce organ failure, complications, and mortality.
• The treatment of ACLF includes antiviral and supportive pharmacological approaches such as lamivudine, entecavir, and tenofovir disoproxil fumarate (for hepatitis B virus (HBV)-related ACLF) to reduce viral load, inflammation, and complications, with liver transplantation remaining the definitive option for patients who do not respond to medical therapy despite limitations related to cost, donor availability, and eligibility.
• Various prognostic models for ACLF include Chronic Liver Failure Consortium (CLIF-C ACLF) (Europe), Asian Pacific Association for the Study of the Liver (APASL) ACLF Research Consortium (AARC) score AARC (Japan), and North American Consortium for the Study of End-Stage Liver Disease (NACSELD) (US). These reflect regional variations in etiology and care, supporting mortality prediction, transplant decisions, and tailored clinical strategies.
• Currently, there is no approved treatments for ACLF. The pipeline is scarce, with few key players. These include Yaqrit Discovery (YAQ005), Seal Rock Therapeutics and GENFIT (SRT-015), GENFIT (G1090N [nitazoxanide] capsules), among others. Players, such as Celloram and Genfit (CLM-022) and CRISPR Medicine Media (bbHEP01), are investigating their products in early stages of development. In addition to therapies, a few players are also evaluating certain devices, including Miromatrix Medical (miroliverELAP) and Yaqrit Discovery (YAQ002).

DelveInsight's 'Acute on Chronic Liver Failure (ACLF)- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the ACLF, historical and forecasted epidemiology, as well as the ACLF market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The ACLF market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, ACLF patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in ACLF and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Acute on Chronic Liver Failure (ACLF) Market

• Rising ACLF Prevalence

The increasing prevalence of ACLF, particularly among females, is a primary driver of ACLF market expansion, supported by the rising burden of chronic liver diseases, growing awareness and diagnosis rates, and the increasing demand for effective targeted treatment options.

• Rising Opportunities in Targeted ACLF Therapies

Emerging understanding of the gut-liver axis, systemic inflammation, and immune dysregulation in ACLF highlights growing opportunities for drug developers to focus on targeted therapies that reduce organ failure, control inflammation, and improve survival outcomes in patients with advanced liver disease.

• Emerging ACLF Competitive Landscape

The pipeline for ACLF remains limited, with no approved targeted therapies currently available. Some of the ACLF drugs in clinical development include YAQ005 (Yaqrit Discovery), SRT-015 (Seal Rock Therapeutics/GENFIT), G1090N (GENFIT), and others.

Acute on Chronic Liver Failure (ACLF) Understanding and Treatment Algorithm

Acute on Chronic Liver Failure (ACLF) Overview and Diagnosis

ACLF is a rapidly progressing complication of chronic liver disease or cirrhosis marked by acute hepatic decompensation and multi-organ failure, leading to high short-term mortality. Common manifestations include jaundice, ascites, hepatic encephalopathy, gastrointestinal bleeding, and infections, often triggered by bacterial infections, alcohol-related injury, viral hepatitis reactivation, or drug-induced liver damage.

ACLF is diagnosed through clinical evaluation, laboratory investigations, and assessment of organ failure in patients with chronic liver disease or cirrhosis. Diagnostic workup includes liver and kidney function tests, coagulation profile, CBC, viral markers, blood cultures, and imaging studies to identify triggers and complications, while severity and prognosis are commonly evaluated using MELD and CLIF-C ACLF scoring systems.

Acute on Chronic Liver Failure (ACLF) Treatment

The primary goals of ACLF treatment are to stabilize liver function, manage organ failure, control systemic inflammation and infections, and improve survival while bridging eligible patients to liver transplantation. Management is largely supportive and multidisciplinary, including intensive care support, albumin infusion, renal replacement therapy, plasma exchange, and mechanical ventilation when required. Pharmacologic therapies include antibiotics such as meropenem, antivirals including entecavir and tenofovir, terlipressin for hepatorenal syndrome, lactulose and rifaximin for hepatic encephalopathy, and prednisolone in selected patients with alcohol-associated hepatitis. Liver transplantation remains the only definitive treatment for advanced ACLF.

Acute on Chronic Liver Failure (ACLF) Unmet Needs

The section "unmet needs of ACLF" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of effective targeted therapies to reverse liver failure and multi-organ dysfunction

2. High short-term mortality despite intensive supportive care

3. Limited availability and accessibility of liver transplantation

4. Need for earlier diagnosis and reliable predictive biomarkers, and others.....

Acute on Chronic Liver Failure (ACLF) Epidemiology

Key Findings from Acute on Chronic Liver Failure (ACLF) Epidemiological Analysis and Forecast

• ACLF is highly prevalent among hospitalized patients with decompensated cirrhosis, with significant regional variations in disease burden and severity across Europe, Asia, and America.
• The observed female predominance and earlier onset of ACLF highlight the importance of early disease monitoring, timely diagnosis, and improved access to preventive and supportive care strategies to reduce disease progression and mortality.

Acute on Chronic Liver Failure (ACLF) Drug Chapters & Competitive Analysis

The ACLF drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the ACLF treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the ACLF therapeutics market.

Approved Therapies for Acute on Chronic Liver Failure (ACLF)

ACLF remains a significant unmet need due to the lack of approved targeted therapies and limited efficacy of current supportive care, creating strong opportunities for innovative drug development and future research advancements.

Acute on Chronic Liver Failure (ACLF) Pipeline Analysis

YAQ005: Yaqrit Discovery

YAQ005, developed by Yaqrit Discovery, is an orally administered non-absorbable carbon-based adsorbent designed to reduce systemic inflammation and toxin accumulation in patients with ACLF. The therapy works by adsorbing endotoxins, inflammatory mediators, and gut-derived harmful substances within the gastrointestinal tract, thereby limiting their translocation into systemic circulation. By targeting the gut-liver axis, YAQ005 aims to decrease immune dysregulation, reduce organ dysfunction, and improve clinical outcomes while maintaining a favorable safety and tolerability profile.

SRT-015: Seal Rock Therapeutics/GENFIT

SRT-015, developed by Seal Rock Therapeutics in collaboration with GENFIT, is an investigational ASK1 (apoptosis signal-regulating kinase 1) inhibitor being evaluated for the treatment of ACLF. The therapy is designed to reduce excessive inflammation, hepatocellular injury, and multi-organ dysfunction associated with ACLF progression. By targeting key inflammatory and stress-response pathways, SRT-015 aims to improve liver function, limit tissue damage, and enhance survival outcomes in patients with severe liver decompensation.

Acute on Chronic Liver Failure (ACLF) Key Players, Market Leaders and Emerging Companies

• Yaqrit Discovery
• Seal Rock Therapeutics
• GENFIT, and others

Acute on Chronic Liver Failure (ACLF) Drug Updates

• As of the December 2025 update, the APACHE trial evaluating short-term survival in patients with ACLF treated with Plasma exchange with human serum Albumin 5%, sponsored by Grifols Therapeutics, was terminated for corporate business reasons unrelated to safety.
• In September 2025, Genfit discontinued the development of VS-01 in ACLF after a patient suffered a serious adverse event in a Phase II trial.

Drug Class Insights

Acute on Chronic Liver Failure (ACLF) Market Outlook

ACLF market is undergoing a significant transformation, moving beyond supportive care and liver transplantation toward targeted, mechanism-driven therapeutic approaches. The growing development of novel agents such as gut-targeted adsorbents, immune-modulators, and anti-inflammatory therapies reflects a shift toward addressing the underlying drivers of systemic inflammation, immune dysregulation, and multi-organ failure in ACLF. These advancements validate innovative strategies focused on the gut-liver axis, cytokine modulation, and organ protection, while strengthening clinical and regulatory interest in next-generation ACLF therapies and reshaping the competitive landscape.

With the continued advancement of pipeline candidates such as YAQ005, SRT-015, and other emerging therapies targeting inflammation and organ dysfunction, the ACLF treatment landscape is evolving similarly to other high-mortality critical care conditions where therapeutic innovation is driving broader clinical development. The United States is expected to remain a major ACLF market due to increasing disease burden, improved diagnostic capabilities, rising awareness of advanced liver diseases, and greater access to specialized care and liver transplantation services compared with several other global markets.

Overall, the introduction of differentiated therapies, increasing research into inflammation-driven liver diseases, improvements in critical care management, and rising awareness among high-risk populations such as patients with cirrhosis, alcohol-related liver disease, and viral hepatitis are expected to drive growth in the ACLF market during the forecast period, creating significant commercial opportunities for both approved products and emerging pipeline therapies

• According to the estimates, the United States accounted for the largest share of the ACLF market among the major markets during the study period.
• The ACLF market is evolving as treatment focus shifts from conventional supportive care and liver transplantation toward targeted therapies addressing systemic inflammation, immune dysregulation, and gut-liver axis dysfunction, with emerging candidates such as YAQ005, SRT-015, and G1090N driving interest due to their potential to improve survival outcomes and reduce multi-organ failure.
• Regional market dynamics show the US leading in research activity and revenue potential, while Europe and Japan demonstrate growing clinical interest driven by rising liver disease burden, increasing awareness of ACLF diagnosis, and expanding development of novel therapeutic approaches.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Acute on Chronic Liver Failure (ACLF) (2022-2036 Forecast)

The ACLF market comprises supportive care therapies, liver transplantation, anti-inflammatory and immunomodulatory agents, gut-targeted therapies, and emerging regenerative approaches, each addressing distinct aspects of systemic inflammation, organ failure, and disease progression in ACLF.

• Supportive care therapies: Standard management approaches such as albumin (HUMAN ALBUMIN), antibiotics, terlipressin, lactulose, rifaximin, and renal replacement therapy remain the backbone of ACLF treatment, helping stabilize patients and manage complications, although they provide limited impact on long-term survival.
• Liver transplantation: Liver transplantation remains the only definitive curative option for eligible patients with advanced ACLF, significantly improving survival outcomes, but its use is restricted by donor shortages, high costs, and limited patient eligibility.
• Anti-inflammatory and immunomodulatory agents: Emerging therapies such as SRT-015 and G1090N are being developed to target systemic inflammation, immune dysregulation, and cytokine imbalance, with the goal of reducing organ failure progression and improving survival outcomes.
• Gut-targeted therapies: Novel agents such as YAQ005, lactulose, and rifaximin aim to reduce bacterial translocation, gut-derived toxins, and systemic inflammation, representing an important area of innovation in ACLF management.
• Regenerative and cell-based therapies: Stem cell therapies, granulocyte colony-stimulating factor (G-CSF), and regenerative approaches are being explored to promote liver repair, restore hepatic function, and potentially delay or reduce the need for transplantation in severe cases.

Supportive care therapies and liver transplantation currently dominate the ACLF treatment landscape, while immunomodulatory, gut-targeted, and regenerative therapies are shaping the future innovation pipeline and driving next-generation therapeutic development in ACLF.

Acute on Chronic Liver Failure (ACLF) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the ACLF market's uptake by drugs, patient uptake by therapy, and sales of each drug.

Market Access and Reimbursement of ACLF

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Acute on Chronic Liver Failure (ACLF) Therapies Price Scenario & Trends

Pricing and analogue assessment of ACLF therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Industry Experts and Physician Views for Acute on Chronic Liver Failure (ACLF)

To keep up with ACLF market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the ACLF emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in ACLF, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 6+ KOLs in the 7MM. Centers such as the University of Mississippi Medical Center, University of Bologna, and Teikyo University School of Medicine, etc. were contacted. Their opinion helps understand and validate current and emerging ACLF therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in ACLF.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of Acute on Chronic Liver Failure (ACLF), strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of ACLF, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the ACLF market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM ACLF market.

Report Insights

• Acute on Chronic Liver Failure (ACLF) Patient Population Forecast
• Acute on Chronic Liver Failure (ACLF) Therapeutics Market Size
• Acute on Chronic Liver Failure (ACLF) Pipeline Analysis
• Acute on Chronic Liver Failure (ACLF) Market Size and Trends
• Acute on Chronic Liver Failure (ACLF) Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year Forecast
• Acute on Chronic Liver Failure (ACLF) Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Acute on Chronic Liver Failure (ACLF) Treatment Addressable Market (TAM)
• Acute on Chronic Liver Failure (ACLF) Competitive Landscape
• Acute on Chronic Liver Failure (ACLF) Major Companies Insights
• Acute on Chronic Liver Failure (ACLF) Price Trends and Analogue Assessment
• Acute on Chronic Liver Failure (ACLF) Therapies Drug Adoption/Uptake
• Acute on Chronic Liver Failure (ACLF) Therapies Peak Patient Share analysis

Report Assessment

• Acute on Chronic Liver Failure (ACLF) Current Treatment Practices
• Acute on Chronic Liver Failure (ACLF) Unmet Needs
• Acute on Chronic Liver Failure (ACLF) Clinical Development Analysis
• Acute on Chronic Liver Failure (ACLF) Emerging Drugs Product Profiles
• Acute on Chronic Liver Failure (ACLF) Market Attractiveness
• Acute on Chronic Liver Failure (ACLF) Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Acute on Chronic Liver Failure (ACLF) market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Acute on Chronic Liver Failure (ACLF)?
• What are the disease risks, burdens, and unmet needs of Acute on Chronic Liver Failure (ACLF)? What will be the growth opportunities across the 7MM concerning the patient population with Acute on Chronic Liver Failure (ACLF)?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Iron deficiency anemia (ACLF)? What are the current guidelines for treating Acute on Chronic Liver Failure (ACLF) in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Acute on Chronic Liver Failure (ACLF) market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.